Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 12, 2007 - Issue 3
Submit an article Journal homepage
163
Views
27
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for hyperphosphatemia

Guido Bellinghieri University of Messina, Division of Nephrology and Dialysis, Policlinico Universitario, Viale Gazzi – 98100, Messina, Italy +39 090 2212339; +39 090 2925899; [email protected]
,
Domenico Santoro University of Messina, Division of Nephrology and Dialysis, Policlinico Universitario, Viale Gazzi – 98100, Messina, Italy +39 090 2212339; +39 090 2925899; [email protected]
&
Vincenzo Savica University of Messina, Division of Nephrology and Dialysis, Policlinico Universitario, Viale Gazzi – 98100, Messina, Italy +39 090 2212339; +39 090 2925899; [email protected]
Pages 355-365 | Published online: 17 Sep 2007

Bibliography

  • GUÉRIN AP, LONDON GM, MARCHAIS SJ, METIVIER F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol. Dial. Transplant. (2000) 15:1014-1021.
  • GOODMAN WG, GOLDIN J, KUIZON BD et al.: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. (2000) 342:1478-1483.
  • MOE SM, O'NEILL KD, RESLEROVA M, FINEBERG N, PERSOHN S, MEYER CA: Natural history of vascular calcification in dialysis and transplant patients. Nephrol. Dial. Transplant. (2004) 19(9):2387-2393.
  • MELAMED ML, EUSTACE JA, PLANTINGA L et al.: Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int. (2006) 70(2):351-357.
  • BLOCK GA, PORT FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am. J. Kidney Dis. (2000) 35:1226-1237.
  • BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. (1998) 31:601-617.
  • EKNOYAN G, LEVIN NW: Impact of the new K/DOQI guidelines. Blood Purif. (2002) 20(1):103-108.
  • NOORDZI JM, KOREVAAR JC, BOESCHOTEN EW, DEKKER FW, BOS WJ, KREDIET RT: Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group. The kidney disease outcomes quality initiative (K/DOQI) Guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am. J. Kidney Dis. (2005) 46(5):925-932.
  • BLOCK GA, KLASSEN PS, LAZARUS JM, OFSTHUN N, LOWRIE EG, CHERTOW GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. (2004) 15(8):2208-2218.
  • KOPPLE JD: National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am. J. Kidney Dis. (2001) 37(1 Suppl. 2):S66-S70.
  • GOTCH FA, PANLILIO F et al.: A kinetic model of inorganic phosphorus mass balance in hemodialysis therapy. Blood Purif. (2003) 21(1):51-57.
  • TOUSSAINT N, BODDINGTON J, SIMMONDS R, WALDRON C, SOMERVILLE C, AGAR J: Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis. Hemodial. Int. (2006) 10(3):280-6.
  • DELMEZ JA, SLATOPOLSKY E, MARTIN KJ, GEARING BN, HARTER HR: Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysis. Kidney Int. (1982) 21(6):862-867.
  • ALFREY AC, LEGENDRE GR, KAEHNY WD: The dialysis encephalopathy syndrome. Possible aluminum intoxication. N. Engl. J. Med.(1976) 294(4):184-188.
  • MOLONY DA, MURTHY B: Accumulation of metals and minerals from phosphate binders. Blood Purif. (2005) 23(Suppl. 1):2-11 (Review).
  • WILHELM M, JAGER DE, OHNESORGE FK: Aluminum toxicokinetics. Pharmacol. Toxicol. (1990) 66(1):4-9 (Review).
  • MOLITORIS BA, FROMENT DH, MACKENZIE TA, HUFFER WH, ALFREY AC: Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int. (1989) 36(6):949-953.
  • SLATOPOLSKY E, WEERTS C, LOPEZ-HILKER S et al.: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N. Engl. J. Med. (1986) 315:157-161.
  • SLATOPOLSKY E, WEERTS C, NORWOOD K et al.: Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int. (1989) 36(5):897-903.
  • LONDON GM, GUERIN AP, MARCHAIS SJ, METIVIER F, PANNIER B, ADDA H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol. Dial. Transplant. (2003) 18(9):1731-1740.
  • SALUSKY IB, KUIZON BD, BELIN TR et al.: Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int. (1998) 54(3):907-914.
  • KURZ P, MONIER-FAUGERE MC, BOGNAR B et al.: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. (1994) 46(3):855-861
  • LONDON GM, MARTY C, MARCHAIS SJ, GUERIN AP, METIVIER F, DE VERNEJOUL MC: Arterial calcifications and bone histomorphometry in end-stage renal disease. J. Am. Soc. Nephrol. (2004) 15(7):1943-1951.
  • National Kidney Foundation: K/DOQI clinical practisce guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. (2003) 42(Suppl. 3):S12-S28.
  • MILLINER DS, ZINSMEISTER AR, LIEBERMAN E, LANDING B: Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int. (1990) 38(5):931-936.
  • EMMETT M, SIRMON M, KIRKPATRICK W, NOLAN CR, SCHMITT GW, CLEVELAND MVB: Calcium acetate control of serum phosphorus in hemodialysis patients. Am. J. Kidney Dis. (1991) 5:544-550.
  • NOLAN CR, CALIFANO JR, BUTZIN CA: Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int. (1990) 38(5):937-941.
  • GUILLOT AP, HOOD VL, RUNGE CF, GENNARI FJ: The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron (1982) 30(2):114-117.
  • DELMEZ JA, KELBER J, NORWORD KY, GILES KS, SLATOPOLSKY E: Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int. (1996) 49(1):163-167.
  • BURKE SK, SLATOPOLSKY E, GOLDBERG DI: Renagel, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol. Dial. Transplant. (1997) 12:1640-1644.
  • GOLDBERG DI, DILLON MA, SLATOPOLSKY E et al.: Effect of Renagel, a non absorbed, calcium and aluminum free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end stage renal disease patients. Nephrol. Dial. Transplant. (1998) 13:2303-2310.
  • BLEYER AJ, BURKE SK, DILLON M et al.: A comparison of the calcium-free phosphate binder sevelamer hydrocloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am. J. Kidney Dis. (1999) 33:694-701.
  • CHERTOW GM, BURKE SK, DILLON MA, SLATOPOLSKY E: For the Renagel Study Group. Long-term effects of sevelamer hydrocloride on the calcium × phosphate product and lipid profile of hemodialysis patients. Nephrol. Dial. Transplant. (1999) 14:2907-2914.
  • QUNIBI WY, HOOTKINS RE, MCDOWELL LL et al.: Treatment of hyperphosphatemia in hemodialysis patients: the calcium acetate renagel evaluation (CARE study). Kidney Int. (2004) 65(5):1914-1926.
  • COLLINS AJ, ST PETER WL, DALLESKA FW, EBBEN JP, MA JZ: Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin. Nephrol. (2000) 54(4):334-341 (Review).
  • NAGANO N, MIYATA S, ABE M, WAKITA S, KOBAYASHI N, WADA M: Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency. Nephrol. Dial. Transplant. (2006) 21:634-643.
  • RAGGI P: Detection and quantification of cardiovascular calcifications with electron beam tomography to estimate risk in hemodialysis patients. Clin. Nephrol. (2000) 54:325-333.
  • RAGGI P: Effects of excess calcium load on the cardiovascular system measured with electron beam tomography in end-stage renal disease. Nephrol. Dial. Transplant. (2002) 17:332-335.
  • CHERTOW GM, BURKE SK, RAGGI P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. (2002) 62:245-252.
  • BLOCK GA, SPIEGEL DM, EHRLICH J et al.: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. (2005) 68(4):1815-1824.
  • BLOCK GA, RAGGI P, BELLASI A, KOOIENGA L, SPIEGEL DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. (2007) 71(5):438-441.
  • FERRAMOSCA E, BURKE S, CHASAN-TABER S, RATTI C, CHERTOW GM, RAGGI P: Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am. Heart J. (2005) 149(5):820-825.
  • LOCATELLI F, D'AMICO M, PONTORIERO G: Lanthanum carbonate. Drugs (2003) 6: 688-695.
  • PENNICK M, DENNIS K, DAMMENT SJ: Absolute bioavailability and disposition of Lanthanum in healthy human subjects administered lanthanum carbonate. J. Clin. Pharmacol. (2006) 46(7):738-746.
  • JOY MS, FINN WF: Randomized, double-blind, placebocontrolled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am. J. Kidney Dis. (2003) 42:96-107.
  • HUTCHISON AJ, MAES B, VANWALLEGHEM J et al.: Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin. Pract. (2006) 102(2):C61-C71.
  • FREEMONT AJ, HOYLAND JA, DENTON J; LANTHANUM CARBONATE SPD405-303 STUDY GROUP: The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin. Nephrol. (2005) 64(6):428-437.
  • LACOUR B, LUCAS A, AUCHERE D, RUELLAN N, DE SERRE PATEY NM, DRUEKE TB: Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. (2005) 67(3):1062-1069.
  • SLATOPOLSKY E, LIAPIS H, FINCH J: Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int. (2005) 68(6):2809-2813.
  • YANG Z, SCHRYVERS D, ROELS F, D'HAESE PC, DE BROE ME: Demonstration of lanthanum in liver cells by energy-dispersive X-ray spectroscopy, electron energy loss spectroscopy and high-resolution transmission electron microscopy. J. Microsc. (2006) 223(Part 2):133-139.
  • BEN-DOV IZ, PAPPO O, SKLAIR-LEVY M et al.: Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats. Nephrol. Dial. Transplant. (2007) 22(2):362-368.
  • LAC G: Saliva assays in clinical and research biology. Pathol. Biol. (2001) 49:660-667.
  • SAVICA V, CALO LA, CALDARERA R et al.: Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia. Nephron Physiol. (2007) 105(3):52-55.
  • DATE T, SHIGEMATSU T, KAWASHITA Y, SATAKE N, MORITA K: Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients. Nephrol. Dial. Transplant. (2003) 18 (Suppl. 3):90-93.
  • HERGESELL O, RITZ E: Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol. Dial. Transplant. (1999) 14:863-867.
  • KUHLMANN MK: Practical approaches to management of hyperphosphatemia: can we improve the current situation? Blood Purif. (2007) 25(1):120-124.
  • YOUNG EW, ALBERT JM, SATAYATHUM S et al.: Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int. (2005) 67(3):1179-1187.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.